STOCK TITAN

[8-K] Adagio Medical Holdings, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Adagio Medical Holdings (ADGM) filed an 8-K announcing the closing of its previously announced private placement. The update references the earlier 8-K reporting entry into a Securities Purchase Agreement with certain accredited investors.

The company furnished a press release as Exhibit 99.1, dated October 20, 2025, which is incorporated by reference.

Adagio Medical Holdings (ADGM) ha depositato un 8-K annunciando la chiusura del suo collocamento privato precedentemente annunciato. L'aggiornamento fa riferimento all'8-K precedente che riferisce l'ingresso in un Securities Purchase Agreement con alcuni investitori accreditati.

L'azienda ha fornito un comunicato stampa come Exhibit 99.1, datato 20 ottobre 2025, che viene incorporato per riferimento.

Adagio Medical Holdings (ADGM) presentó un 8-K anunciando el cierre de su colocación privada previamente anunciada. La actualización hace referencia al 8-K anterior que reporta la entrada en un Securities Purchase Agreement con ciertos inversores acreditados.

La empresa adjuntó un comunicado de prensa como Exhibit 99.1, con fecha de 20 de octubre de 2025, que se incorpora por referencia.

Adagio Medical Holdings (ADGM)는 앞서 발표된 비공개 배정의 종료를 공시하는 8-K를 제출했습니다. 업데이트는 특정 공인 투자자들과의 증권 매매 계약(Securities Purchase Agreement) 체결을 보고한 이전의 8-K를 참조합니다.

회사는 Exhibit 99.1로 날짜가 2025년 10월 20일인 보도자료를 제공했으며, 이는 참조에 의해 통합됩니다.

Adagio Medical Holdings (ADGM) a déposé un 8-K annonçant la clôture de son placement privé précédemment annoncé. La mise à jour fait référence à l'entrée antérieure dans un Securities Purchase Agreement avec certains investisseurs accrédités.

La société a fourni un communiqué de presse sous Exhibit 99.1, daté du 20 octobre 2025, qui est incorporé par référence.

Adagio Medical Holdings (ADGM) hat ein 8-K eingereicht, das den Abschluss seiner zuvor angekündigten privaten Platzierung meldet. Das Update verweist auf das frühere 8-K, das den Abschluss eines Securities Purchase Agreement mit bestimmten akkreditierten Investoren meldet.

Das Unternehmen hat eine Pressemitteilung als Exhibit 99.1, datiert auf den 20. Oktober 2025, vorgelegt, die durch Bezugnahme einbezogen ist.

Adagio Medical Holdings (ADGM) قدّمت ملف 8-K يعلن إغلاق طرحها الخاص الذي تم الإعلان عنه سابقاً. يشير التحديث إلى الـ 8-K السابق الذي يعلن الدخول في اتفاق شراء الأوراق المالية مع بعض المستثمرين المعتمدين.

قدمت الشركة بياناً صحفياً كـ Exhibit 99.1، بتاريخ 20 أكتوبر 2025، يدرج بالمرجع.

Adagio Medical Holdings (ADGM) 提交了8-K,宣布收盘其先前宣布的私募发行。更新提及早前的8-K,披露与某些合格投资者签订的证券购买协议。

公司以 Exhibit 99.1 的形式提供了一份新闻稿,日期为 2025 年 10 月 20 日,且被通过引用并入。

Positive
  • None.
Negative
  • None.

Insights

Closing of a previously announced private placement is confirmed; impact depends on absent terms and structure details.

Adagio Medical Holdings reported the Closing of its previously announced private placement with accredited investors under a Securities Purchase Agreement. This confirms execution of a financing transaction that had been pending, shifting it from intent to completion. The company furnished a press release as Exhibit 99.1.

Without disclosed terms here—such as security type, pricing, proceeds, or any warrant or registration rights—the shareholder impact cannot be quantified. Closings like this often address funding needs but can also introduce dilution or other obligations depending on structure. The lack of specifics in this excerpt keeps the net effect indeterminate.

Focus on the prior October 14, 2025 8-K and the October 20, 2025 press release for concrete terms, including any share issuance, conversion features, or covenants. Key near-term items to track are any follow-on registration undertakings and timing, plus any conditions tied to Nasdaq listing status if referenced in related materials.

Adagio Medical Holdings (ADGM) ha depositato un 8-K annunciando la chiusura del suo collocamento privato precedentemente annunciato. L'aggiornamento fa riferimento all'8-K precedente che riferisce l'ingresso in un Securities Purchase Agreement con alcuni investitori accreditati.

L'azienda ha fornito un comunicato stampa come Exhibit 99.1, datato 20 ottobre 2025, che viene incorporato per riferimento.

Adagio Medical Holdings (ADGM) presentó un 8-K anunciando el cierre de su colocación privada previamente anunciada. La actualización hace referencia al 8-K anterior que reporta la entrada en un Securities Purchase Agreement con ciertos inversores acreditados.

La empresa adjuntó un comunicado de prensa como Exhibit 99.1, con fecha de 20 de octubre de 2025, que se incorpora por referencia.

Adagio Medical Holdings (ADGM)는 앞서 발표된 비공개 배정의 종료를 공시하는 8-K를 제출했습니다. 업데이트는 특정 공인 투자자들과의 증권 매매 계약(Securities Purchase Agreement) 체결을 보고한 이전의 8-K를 참조합니다.

회사는 Exhibit 99.1로 날짜가 2025년 10월 20일인 보도자료를 제공했으며, 이는 참조에 의해 통합됩니다.

Adagio Medical Holdings (ADGM) a déposé un 8-K annonçant la clôture de son placement privé précédemment annoncé. La mise à jour fait référence à l'entrée antérieure dans un Securities Purchase Agreement avec certains investisseurs accrédités.

La société a fourni un communiqué de presse sous Exhibit 99.1, daté du 20 octobre 2025, qui est incorporé par référence.

Adagio Medical Holdings (ADGM) hat ein 8-K eingereicht, das den Abschluss seiner zuvor angekündigten privaten Platzierung meldet. Das Update verweist auf das frühere 8-K, das den Abschluss eines Securities Purchase Agreement mit bestimmten akkreditierten Investoren meldet.

Das Unternehmen hat eine Pressemitteilung als Exhibit 99.1, datiert auf den 20. Oktober 2025, vorgelegt, die durch Bezugnahme einbezogen ist.

false 0002006986 0002006986 2025-10-20 2025-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 20, 2025

 

ADAGIO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-42199 99-1151466
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

26051 Merit Circle, Suite 102

Laguna Hills, CA

  92653
(Address of principal executive offices)   (Zip Code)

 

(949) 348-1188 

(Registrant’s telephone number, including area code)

 

Not Applicable 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share ADGM The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 8.01 Other Events

 

On October 20, 2025, Adagio Medical Holdings, Inc. (the “Company”) issued a press release announcing the closing (the “Closing”) of its previously announced private placement, which was the subject of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on October 14, 2025, reporting entry into a Securities Purchase Agreement with certain accredited investors. A copy of the press release announcing the Closing is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated October 20, 2025.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 20, 2025

 

  Adagio Medical Holdings, Inc.
   
  By: /s/ Todd Usen
  Name: Todd Usen
  Title: Chief Executive Officer

 

3

 

FAQ

What did ADGM disclose in this Form 8-K?

The company announced the closing of its previously announced private placement.

When was the closing announcement made?

The press release announcing the closing is dated October 20, 2025.

What exhibit accompanies the 8-K?

A press release is attached as Exhibit 99.1 and incorporated by reference.

What prior filing does this reference?

It references the earlier Form 8-K reporting entry into a Securities Purchase Agreement with accredited investors.

What is ADGM’s stock exchange and symbol?

Common stock trades on The Nasdaq Stock Market LLC under the symbol ADGM.

Is ADGM an emerging growth company?

Yes, it is identified as an emerging growth company in the filing.
Adagio Medical

NASDAQ:ADGM

ADGM Rankings

ADGM Latest News

ADGM Latest SEC Filings

ADGM Stock Data

22.00M
5.46M
0.29%
87.46%
0.94%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LAGUNA HILLS